The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer  by Shepherd, Frances A. et al.
IASLC STAGING ARTICLE
The International Association for the Study of Lung Cancer
Lung Cancer Staging Project: Proposals Regarding the
Clinical Staging of Small Cell Lung Cancer in the
Forthcoming (Seventh) Edition of the Tumor, Node,
Metastasis Classification for Lung Cancer
Frances A. Shepherd, MD, FRCPC,* John Crowley, PhD,† Paul Van Houtte, MD,‡
Pieter E. Postmus, MD, PhD, Desmond Carney, MD, PhD,¶ Kari Chansky, MS,†
Zeba Shaikh, BSc,** and Peter Goldstraw, FRCS,
on behalf of the International Association for the Study of Lung Cancer International Staging
Committee and Participating Institutions
Background: Small cell lung cancer (SCLC) is usually classified
using the limited and extensive definition. The tumor, node, metas-
tasis (TNM) classification should also be applicable to SCLC, but it
has only been reported in small surgical series. The current analysis
looks to the impact of the TNM system on the clinical staging of
SCLC and of the new International Association for the study of
Lung Cancer (IASLC) proposals.
Methods: Using the IASLC database, survival analyses were per-
formed for clinically staged patients. Prognostic groups were com-
pared, and the new IASLC TNM proposals were applied to this
population and to the Surveillance, Epidemiology, and End Results
(SEER) database.
Results: The IASLC database contained 12,620 eligible cases of
small cell histology. TNM staging was available for 8088 patients.
Survival was directly correlated to both T and N category. Differ-
ences were more pronounced in patients without mediastinal or
supraclavicular nodal involvement. Stage grouping using the sixth
edition of TNM also differentiates survival except between IA and
IB. Patients with pleural effusion regardless of the cytology have an
intermediate prognosis between limited and extensive disease. The
IASLC proposals for the seventh edition of the TNM classification
also apply to this series of SCLC and to the SEER database.
Conclusion: TNM staging is recommended for SCLC, and stratifi-
cation by stage I-III should be incorporated in clinical trials of
early-stage disease. Further studies are needed to clarify the impact
of pleural effusion and the extent of N3 disease.
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Lung cancer is the leading cause of cancer-related mortalityin the western world, with recent statistics showing that it
accounts for more than 1,000,000 deaths each year globally.1
Small cell lung cancer (SCLC) represents only 15% to 20%
of lung cancers overall, with incidence rates declining among
men but continuing to increase among women in most coun-
tries.2 It is distinguished by its rapid growth rate, early
dissemination to regional lymph nodes and distant sites, and
its sensitivity to chemotherapy and radiotherapy.3 The intro-
duction of chemotherapy to the treatment of SCLC led to
significant improvements in median and 5-year survival rates
in the 1970s through 1990s,4 but recently survival seems to
have reached a plateau for both localized and advanced
SCLC.
Staging of lung cancer is second in importance only to
the pathologic determination of cell type. Accurate staging
provides prognostic information, and stage determines treat-
ment strategies for all types of lung cancer. The first staging
system for SCLC was introduced in the 1950s by the Veter-
ans’ Administration Lung Study Group (VALSG) for use in
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their randomized clinical trials.5 This simple system divided
SCLC into two disease subgroups termed “limited” and “exten-
sive” disease. Limited disease (LD) was characterized by tumors
confined to one hemithorax, although local extension and ipsi-
lateral, supraclavicular nodes could also be present if they could
be encompassed in the same radiation portal as the primary
tumor. No extrathoracic metastases could be present. All other
disease was classified as extensive disease (ED).
In 1989, the International Association for the Study of
Lung Cancer (IASLC) issued a consensus report6 that, for the
first time in 30 years, introduced changes to the VALSG
staging system. This report suggested that LD should be
expanded to include tumors limited to one hemithorax with
regional lymph node metastases, including hilar, ipsilateral
and contralateral mediastinal and ipsilateral and contralateral
supraclavicular nodes. They also recommended that patients
with ipsilateral pleural effusion, regardless of whether cytol-
ogy is positive or negative, be considered to have LD if no
extrathoracic metastases were detected.
The tumor, node, metastasis (TNM) staging systems of
the American Joint Committee on Cancer Staging (AJCC)7
and the Union Internationale Contre le Cancer (UICC)8 are
also applicable to SCLC, but they are used less frequently in
clinical practice because these two staging systems have
historically relied on surgical confirmation for their accuracy,
and patients with SCLC seldom present at a stage for which
surgery is appropriate. However, in small surgical series of
patients with SCLC, the TNM staging system has been shown
to be prognostic of outcome.9–21 TNM staging in non-surgical
series is rarely reported.22,23
The IASLC has established a database containing stag-
ing and a minimum of 5-year survival data for more than
100,000 patients with lung cancer from around the world,
presenting between 1990 and the end of 2000. Among these
are more than 12,000 patients with SCLC. This database was
established to assess the current stage categories as defined by
the AJCC7 and the UICC sixth edition,8 with the goal of
redefining and regrouping of T and N descriptors, to make
recommendations for change if and where appropriate. These
analyses were performed initially on the large 67,725 case
non-small cell lung cancer (NSCLC) database,24–27 then ap-
plied to the smaller SCLC cohort. Proposed changes for the
UICC seventh edition for NSCLC that are relevant for SCLC
are mainly those that result in changes to T staging. It has
been recommended that large sized tumors (7 cm) be-
come T3; additional nodules within the same lobe as the
primary tumor also become T3; ipsilateral intrapulmonary
nodules in other lobes become T4; and all pleural effusions
regardless of cytology become M1. It is also recommended
that pleural effusions in the absence of other metastatic sites
be designated M1a, with M1b reserved for all other meta-
static involvement.24,26
We herein report our analysis of clinical TNM staging
for SCLC using the current sixth edition TNM staging system
for lung cancer and compare this with the proposed new
groupings as defined by the IASLC analyses in NSCLC. We
focus on the clinical staging of SCLC because fewer than 5%
of patients are eligible for pathologic surgical staging.
METHODS
Statistical Analysis
The database on which these analyses are based was
created by the IASLC to inform revisions for the seventh
edition of the UICC TNM Classification of Malignant Tumors
staging manual in lung cancer due to be published early in
2009. To be eligible for inclusion in the IASLC database,
patients were required to have a new diagnosis of either
SCLC or NSCLC, an initial presentation from 1990 to the end
of 2000, adequate staging information at baseline, and ade-
quate follow-up for survival.
There were no minimal staging requirements for inclu-
sion in the database, and details of staging were not recorded.
TNM stage groupings for NSCLC were developed
based on recommendations made by the individual T, N, and
M subcommittees for changes to their respective components.
Using these modified categories, a small number of candidate
stage grouping schemes were developed, initially using a
recursive partitioning and amalgamation algorithm.28 The
analysis grouped patients based on best stage (pathological if
available, otherwise clinical) after determination of best-split
points based on overall survival on indicator variables for the
newly proposed T/M category and an ordered variable for N
category. This analysis was performed on a randomly se-
lected training set comprising two thirds of the available data
that met the requirements for conversion to the newly pro-
posed TNM categories (n 17,726), reserving 9133 cases for
later validation. The random selection process was stratified
by type of database submission and time of case entry
(1990–1995 vs 1995–2000).29 Selection of a final stage
grouping proposal from among the candidate schemes was
based on its statistical properties in the training set and its
relevance to clinical practice and was arrived at by consensus.
Analyses focusing on sixth edition TNM were applied
to the subset of SCLC cases for which complete clinical TNM
stage was provided. The newly proposed TNM stage group-
ings were applied to the set of SCLC cases that had sufficient
descriptors to reclassify according to the new TNM stage
scheme. Analyses focusing on pleural effusion required only
a designation of limited or extensive stage disease by the
VALSG system (or adequate TNM staging to derive this
determination) and sufficient information to determine pres-
ence/absence of pleural effusion.
Survival was measured from the date of entry (date of
diagnosis for registries and the date of registration for proto-
cols) and was estimated by the Kaplan-Meier method. Prog-
nostic groups were compared formally by Cox proportional
hazards regression analysis, using the SAS System for Win-
dows Version 9.0 PHREG procedure.
RESULTS
Population
Of the 100,869 patients with information submitted to
the IASLC database, 81,015 met the initial screening require-
ments of having a new diagnosis rather than recurrent diag-
nosis of either SCLC or NSCLC, presentation from 1990 to
the end of 2000, adequate follow-up for survival, and ade-
quate staging information at baseline. From the 13,290 SCLC
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cases meeting the initial screen, 670 with mixed histology or
with conflicts between TNM and extent of disease were
excluded, to yield 12,620 eligible cases of small cell histol-
ogy. Of the 12,620 eligible SCLC cases, 4532 had LD or ED
classification only (Table 1). TNM staging was available for
8088 patients: 3430 cM0 cases had full clinical TNM data,
343 had full pathologic TNM staging, and 4530 were classi-
fied as cM1 (clinical metastatic disease). The 12,620 cases
originated from four global regions: Europe (56%), North
America (35%), Asia (3%), and Australia (6%). Of the cases,
52% were from clinical trials, 43% from population-based
registries or single-institution series or registries, and the rest
from consortia. For cases with complete clinical TNM stag-
ing, the proportions were: clinical trials 32%, population-
based registries or single-institution series or registries 60%,
and consortia 8% (Table 2). Because most patients with
SCLC are staged only clinically, we focus on the clinical
staging of this malignancy in this article; the surgical series
will be reported separately. A complete listing of data con-
tributors is given in Appendix A.
T Category
As shown in Figure 1 A, increasing clinical T category,
using the sixth edition TNM staging system was associated
with progressively lower survival in patients who did not
have evidence of metastatic (M1) involvement. Comparisons
between T categories and 1- and 5-year survival rates are
shown in Table 3. Patients with clinical T1 had significantly
better survival than those with T categories 2–4. A compar-
ison of clinical category T1 versus T2 yields a hazard ratio
(HR) of 1.48 (p  0.0001), and the trend continues with
significant differences between T2 versus T3 and T3 versus
T4 (see Table 3). The p value for the ordered log rank test (a
test against ordered alternatives for survival data) is less than
0.0001.28,29
N Category
As shown in Figure 1B and Table 4, increasing clinical
N category was associated with progressively lower survival.
Patients with clinical N0 or N1 tumors had significantly better
survival than did those with N2 or N3 tumors. The difference
between cN0 and cN1 is not significant (HR 1.02, p  0.76).
The cN2 and cN3, although significantly different, have
similar median survivals (14 vs. 12 months, HR 1.18). The
difference between the N1 and N2 is the largest (median 19
vs. 14 months, HR 1.40, p  0.0001) and represents the
primary separation for clinical N category. The p value for
the ordered log rank test is less than 0.0001.
Survival for clinical T categories within the four clin-
ical N categories 0–3 is shown in Figure 2. Although increas-
ing T category seems to be associated with worse survival in
each N category, the differences seem to be clinically mean-
ingful only for patients without mediastinal or supraclavicular
nodal involvement.
Survival According to TNM Stage
Survival by clinical TNM stage sixth edition is shown
in Figure 1C . The near superimposition of stage IA together
with IIA, and stage IB with IIB, are most likely a reflection of
the separation between the T1 cases (comprising IA and IIA)
and the T2 and T3 (IB and IIB). Pair-wise comparisons
between adjacent stage groupings are shown in Table 5. All
differences are significant, but for the reason just discussed,
the hazard ratio for IIA versus IB is the reverse of what would
be expected.
Pleural Effusion
In the proposals from the IASLC for the forthcoming
(seventh) edition of the TNM classification for lung cancer,
the presence of a pleural effusion in patients with NSCLC
will now be considered as M1 disease. In the SCLC database,
information concerning the presence or absence of pleural
effusion or other distant sites was available for 1258 patients
with otherwise limited disease (1113 of whom were without
pleural effusion, 145 with pleural effusion) and 4500 patients
with ED with other metastatic sites. Of the 145 cases of LD
with pleural effusion, 81 were actually designated as ED
without any other metastatic sites. These 81 were assumed to
have LD with pleural effusion. Surgically managed cases
were excluded. As can be seen from Figure 3A, the survival
of patients with LD with effusion is intermediate between
those of patients with LD without effusion and patients with
ED (ordered log rank p value 0.0001).
The result of cytologic examination of the pleural
effusion was available for only 68 patients in the database. As
shown in Figure 3B, the survival of patients with LD with
effusion, whether cytologically negative or positive, re-
mained intermediate between those of patients with LD
TABLE 1. Summary of 12,620 Small Cell Lung Cancer Cases from the IASLC International Staging
Project Database
VALSG/IASLC
Stage
Available TNM staging
Clinical
TNM
Pathological
TNM
Clinical and
Pathological TNM cM1
Extensive or
Limited Only Total
Not classified 1819 127 193 1532 0 3671
Extensive 88 0 4 2998 2038 5128
Limited 1308 1 18 0 2494 3821
Total 3215 128 215 4530 4532 12620
VALSG, Veterans’ Administration Lung Study Group; IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node,
metastasis.
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without effusion and patients with ED, and the survival of
patients with LD with positive effusions was superior to that
of patients with ED (ordered log rank p value 0.0001).
Proposals from the IASLC for Stage Groupings in
the Seventh Edition of the TNM Classification for
Lung Cancer
It was not possible to classify all SCLC cases according
to the proposed IASLC stage groupings because details for
the T descriptor frequently was inadequate, particularly with
respect to size, presence of additional intrapulmonary nod-
ules, and involvement of the pleura. Figure 4A shows survival
according to the TNM stage sixth edition for the smaller
cohort of patients (n  2464) with full T descriptor data.
With the exception of the extremely small subgroup of eight
patients with stage IIA, it can be seen that increasing stage is
associated with progressively shorter survival. Figure 4B
shows the survival of the same cohort of patients using the
IASLC stage groupings proposed for the UICC seventh
edition, and Figure 4C shows the proposed IASLC groupings
applied to the much larger Surveillance, Epidemiology and
End Results (SEER) data base of the National Cancer Insti-
tute. In the SEER database, for patients registered with an
initial diagnosis of SCLC during the years 1998 through 2000
inclusive, the proposed IASLC system works well with in-
creasing stage being associated with decreasing survival.
DISCUSSION
At the time of initial diagnosis, approximately two thirds
of patients with SCLC have clinical evidence of hematogenous
metastases (M1); for the remaining one-third, most patients have
clinical evidence of extensive nodal involvement in the hilar,
mediastinal, and sometimes even the supraclavicular regions.
For that reason, surgical resection is seldom offered; instead,
patients are treated with systemic chemotherapy with or without
radiation. Although TNM staging has been applied in small
series of patients with SCLC treated either with surgery alone or
with combined modality therapy including surgery,9–21 a sim-
pler staging system assigning patients to either LD or ED is used
most frequently in clinical practice.5,6 Patients with LD cancers
(confined to the thorax) are treated with chemotherapy and
thoracic radiation, whereas, for the most part, patients with ED
(distant hematogenous metastases) receive only chemotherapy.
In general, it has been believed that more precise
staging of SCLC using the TNM system does not provide
extra guidance with respect to selection of treatment modality
because so few patients are eligible for surgery. However, a
more precise definition of nodal involvement may be of
particular relevance for radiation treatment. The simple des-
ignation of LD does not provide adequate information for
accurate radiotherapy planning because it does not differen-
tiate between the presence or absence of ipsilateral and
contralateral supraclavicular nodes, and ipsilateral and con-
tralateral hilar or mediastinal nodes. According to the 1989
IASLC staging system for SCLC, all of these nodal stations
are included in LD. In the modern era of conformal tech-
niques and increasing radiation dose for SCLC, it is likely no
longer appropriate to treat all patients with LD in the same
way, and radiation fields must be determined using more
precise nodal categories.
The SCLC subgroup of patients in the IASLC staging
initiative represents the largest cohort of patients with this
malignancy ever to be reported. In particular, it is the largest
cohort of patients with SCLC to have been staged using the
TNM system apart from small surgical series, most of which
had fewer than 50 patients.9–21 These surgical series clearly
showed that TNM staging could identify patients with differ-
ent prognoses.
The more important question, however, is whether the
old VALSG and IASLC staging classifications should be
abandoned and whether clinical TNM staging, as used for
NSCLC, should be applied to SCLC as proposed by the
UICC. In our large clinically staged series, patients with
clinical T1 disease had significantly better survival than those
with T2 disease (HR 1.48, p  0.0001) and all other T
categories, although they represented only 13.7% of all pa-
tients. However, the test for trend among the four T groupings
was highly significant. In a pattern of care study performed in
Japan including only patients with limited disease, the T
category was also a significant prognostic factor for survival
in a multivariate analysis.18
TABLE 2. Sources of Small Cell Lung Cancer Cases with Complete TNM Stage
Type of
Database
Available TNM Staging
Clinical
TNM
Pathological
TNM
Clinical and
Pathological TNM cM1 Total
Registry 634 6 9 1720 2369
Surgical series 31 67 3 5 106
Clinical trial 1027 0 1 1556 2584
Series 742 2 31 596 1371
Consortium 240 11 171 263 685
Institutional registry 541 0 0 390 931
Surgical registry 0 42 0 0 42
Total 3215 128 215 4530 8088
TNM, tumor, node, metastasis.
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With respect to N category, patients with clinical N0 or
N1 tumors had significantly better survival than those with
N2 or N3 tumors, although the difference between N0 and N1
was not significant, and the greatest difference in survival
was seen between N1 and N2. It is likely that the patients
with T1-2,N0-1,M0 tumors (i.e., stage IA, IB, IIA and IIB
[N0 and N1]) are the same as those previously classified by
the University of Toronto Lung Group as “very limited.”22
Unfortunately, the database did not contain enough
information to determine whether the survival of patients
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FIGURE 1. Survival by (A) clinical T
Category, (B) clinical N Category, and
(C) clinical TNM category (sixth edi-
tion of TNM).
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with N3 contralateral mediastinal nodes differed from that of
patients with N3 supraclavicular nodes, and it could not
address differences in outcome for ipsilateral versus con-
tralateral supraclavicular nodal involvement. In the IASLC
staging system,6 both ipsilateral and contralateral supracla-
vicular nodes are included in LD. Therefore, more precise
nodal categories should be recorded in future validation
studies that will have prospectively collected data.
In the past, the traditional radiotherapy ports for chest
irradiation for SCLC were large and sometimes included
TABLE 3. Overall Survival Comparisons for Clinical Category T1 to T4 (any N) M0
Small Cell Lung Cancer, IASLC Data
T Category
n
1-yr
Survival (%)
5-yr
Survival (%) Comparison HR p
T1 470 73 29
T2 1396 62 15 T2 vs. T1 1.48 0.0001
T3 564 55 11 T3 vs. T2 1.14 0.0185
T4 1000 49 10 T4 vs. T3 1.17 0.0055
HR, hazard ratio.
TABLE 4. Overall Survival Comparisons for Clinical Category N0–N3 (any T) M0 Small
Cell Lung Cancer, IASLC Database
N Category
n
1-yr
Survival (%)
5-yr
Survival (%) Comparison HR p
N0 750 68 24
N1 348 68 20 N1 vs. N0 1.02 0.7552
N2 1592 56 12 N2 vs. N1 1.40 0.0001
N3 740 50 9 N3 vs. N2 1.18 0.0006
HR, hazard ratio.
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FIGURE 2. Survival by clinical T category, within clinical N categories.
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“prophylactic” treatment of areas such as the contralateral
hilum and both supraclavicular fossae. In essence, therefore,
treatment frequently paralleled the IASLC definition of lim-
ited disease. However, only moderate dose radiation could be
delivered to such large volumes. The inability to deliver high
doses to these large volumes may, in part, explain the high
rates of failure at the primary site reported in most studies
despite the administration of thoracic radiotherapy. Several
recent trends make more precise nodal staging critical for
SCLC. As is the case in NSCLC, reduction of the radiother-
apy field size to cover only the known area of macroscopic
disease is being recommended for SCLC. Also, the high local
failure rate despite the addition of radiation to chemotherapy
is leading to the investigation of higher radiation doses or
TABLE 5. Overall Survival Comparisons for Clinical TNM Stage Category Small Cell
Lung Cancer, IASLC Database
Stage N
1-yr
Survival (%)
5-yr
Survival (%) Comparison HR p
IA 211 77 38
IB 325 67 21 IB vs. IA 1.48 0.0003
IIA 55 85 38 IIA vs. IB 0.62 0.0075
IIB 270 70 18 IIB vs. IIA 1.57 0.0118
IIIA 1170 59 13 IIIA vs. IIB 1.32 0.0003
IIIB 1399 50 9 IIIB vs. IIIA 1.21 0.0001
IV 4530 22 1 IV vs. IIIB 2.16 0.0001
HR, hazard ratio.
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FIGURE 3. Survival by pleural effu-
sion status (surgical cases excluded).
A, All pleural effusions included. B,
Only effusions with cytologic evalua-
tion comparing cytology-positive with
cytology-negative effusion.
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more aggressive combined radio-chemotherapy regimens.30–32
To avoid toxicity from large volume fields, it will be essential
to identify the most appropriate patients for such therapy, and
more precise staging will be key to the ability to do this. It
will also be very important to examine the patient populations
in reports of clinical trials of altered fractionation and high-
dose radiation (particularly single-arm phase I or II studies)
because all patients with LD as defined by the IASLC may
not be included in those studies, and this may have an effect
on the survival outcomes. For example, in the landmark
Turrisi trial, patients with pleural effusions, regardless of the
cytology, and those with contralateral hilar or supraclavicular
adenopathy were excluded.30 In this analysis, the survival of
patients with IIIA and IIIB disease seems to be less than that
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FIGURE 4. Survival by (A) clinical
sixth edition of TNM, including only
those cases with sufficient information
to derive IASLC proposed TNM stage;
(B) IASLC proposed TNM stage; (C )
survival by IASLC proposed TNM
stage in the Surveillance, Epidemiol-
ogy and End Results database.
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reported in recent trials of high-dose radiation, hyperfraction-
ated radiation, or concurrent chemotherapy and radiation
therapy in LD SCLC. This may, in part, be because of less
aggressive treatment practices in some parts of the globe
where concurrent chemotherapy and radiation is seldom ad-
ministered and where high-dose or hyperfractioned radiation
is not considered standard. Alternatively, however, these
survival rates may be a more accurate reflection of the true
outcome of LD SCLC than those reported from clinical trials
in which trial patients are a highly selected subgroup of LD
overall.
If the proposals made by the IASLC for the forthcom-
ing (seventh) edition of the TNM classification for lung
cancer are accepted by the UICC and the AJCC, patients with
pleural effusion will, in the future, be classified as having M1
(or extensive) disease. Our analysis shows that patients who
have pleural effusion without extrathoracic metastases (M1a)
have a survival that is intermediate between that of stage I–III
without effusion and stage IV. A similar observation was
reported by Perng et al. in a series of patients treated in
Taiwan.23 Therefore, we recommend that pleural effusion
should be a stratification parameter in clinical trials for both
LD and ED SCLC. Having even a small proportion of
patients with pleural effusion in LD trials could affect out-
come significantly if they are not balanced between the arms,
as could patients with only a pleural effusion in ED trials.
Unfortunately, we did not have enough patients in our anal-
ysis to make a clear statement concerning cytology-positive
or -negative effusions. Similarly, no information was avail-
able with respect to the presence of a pericardial effusion.
This information must be collected prospectively in future
studies.
It seems that TNM staging can identify subgroups of
patients with distinct prognoses from within the broad defi-
nition of LD. However, the question still remains as to the
value of applying the TNM system of staging to all patients
with LD SCLC. Exact TNM stage is unlikely to alter treat-
ment decisions for most patients with LD because combined
modality therapy will be offered to patients with good per-
formance status in most subsets of stage I, II, or III. The only
potential exception to this might be the subgroup of patients
with N3 supraclavicular nodal involvement, whether unilat-
eral or bilateral. Whether to include supraclavicular nodes in
the radiation treatments field remains an unresolved issue and
is one that will require careful documentation for future
prospective database analyses.
Our analysis suggests that, in the context of clinical
trials in LD, accurate TNM staging may be critical and
suggests that stratification based on TNM stage may be
important. Survivals for clinical stages I and II are signifi-
cantly different from those of stage III with N2 or N3
involvement. Therefore, the SCLC staging subcommittee of
the IASLC Lung Cancer Staging Project recommends that
TNM staging should be applied to SCLC and that stratifica-
tion for stage should be incorporated into all trials in LD
SCLC, particularly those addressing thoracic and prophylac-
tic cranial radiation questions and those that include a surgi-
cal treatment arm. The small survival differences that are
expected in these trials could be affected significantly by
imbalances in the two patient subgroups of stage I/II versus
III. For tumor registries, the clinical and, where possible,
pathologic TNM designations should be recorded. It will
always be possible to derive the LD and ED subsets from
these data.
In summary, the proposals made by the IASLC for the
forthcoming (seventh) edition of the TNM staging system
seem to have relevance to SCLC. The SCLC subcommittee of
the IASLC Lung Cancer Staging Committee therefore rec-
ommends that TNM staging be applied in SCLC and that
stratification by TNM stage be incorporated into clinical trials
in stage I-III SCLC. For prospective staging validation stud-
ies, more information must be collected to define the N
category more clearly and to determine whether there is a
difference in prognosis for patients with cytology-negative or
-positive pleural effusions and for patients with pericardial
effusions. In addition, in future studies, data concerning other
prognostic variables, such as gender and performance status,
and more detailed staging data should also be collected for
multivariate analysis to isolate the effect of stage in this
malignancy.
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